<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072134</url>
  </required_header>
  <id_info>
    <org_study_id>STU00203933</org_study_id>
    <nct_id>NCT03072134</nct_id>
  </id_info>
  <brief_title>Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma</brief_title>
  <official_title>Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant gliomas have a very poor prognosis with median survival measured in months rather
      than years. It is a disease in great need of novel therapeutic approaches. Based on the
      encouraging results of our preclinical studies which demonstrate improved efficacy without
      added toxicity, the paradigm of delivering a novel oncolytic adenovirus via a neural stem
      cell line in combination with radiation and chemotherapy is well-suited for evaluation in
      newly diganosed malignant gliomas. The standard-of-care allows application of virotherapy as
      neoadjuvant therapy and assessment of the cooperative effects with radiation/chemotherapy
      without altering the standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A Phase I study of neural stem cell based virotherapy in combination with standard radiation and chemotherapy for patients with newly diagnosed malignant glioma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum number of neural stem cells loaded with the oncolytic adenovirus.</measure>
    <time_frame>Two years</time_frame>
    <description>We will escalate the number of neural stem cells loaded with the oncolytic adenovirus in each cohort of patients and monitor the neurological exam for development of any neurological side effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor response or progression to treatment on MRI.</measure>
    <time_frame>Two years</time_frame>
    <description>We will monitor patients with serial MRIs over the course of the study to determine whether there is any evidence of tumor regression or progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Glioma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Astrocytoma, Grade III</condition>
  <condition>Astrocytoma, Grade IV</condition>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>Unresectable disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resectable disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neural stem cells loaded with an oncolytic adenovirus</intervention_name>
    <description>The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.</description>
    <arm_group_label>Unresectable disease</arm_group_label>
    <arm_group_label>Resectable disease</arm_group_label>
    <other_name>NSC-CRAd-Survivin-pk7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have presumed malignant glioma based on clinical and radiologic
             evaluation (pathologic confirmation of malignant glioma must be made at the time of
             stereotactic biopsy or resection prior to NSC-CRAd-S-pk7 injection; if this is not
             possible, the injection will not be performed and the subject will no longer be
             eligible for the study).

          -  Tumor must be accessible for injection and must not be located in the brainstem, or
             contained within the ventricular system.

          -  Planning to undergo standard radiation/chemotherapy

          -  18 years of age or older.

          -  Performance status must be KPS ≥ 70

          -  SGOT (AST) &lt; 3x upper limit of normal

          -  Serum creatinine &lt; 2mg/dl

          -  Platelets &gt; 100,000/mm3 and WBC &gt; 3000/mm3

        Exclusion Criteria:

          -  Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection
             but not to exclude patients with a distant history of resolved hepatitis A infection.

          -  Immunosuppressive drugs (with exception of corticosteroid).

          -  Known HIV+ patients.

          -  Acute infections (viral, bacterial or fungal infections requiring therapy).

          -  Pregnant or breast-feeding patients.

          -  Evidence of metastatic disease or other malignancy (except squamous or basal cell skin
             cancers).

          -  Prior radiation therapy to the brain or prior treatment for brain tumor Other serious
             co-morbid illness or compromised organ function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej S Lesniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maciej S Lesniak, MD</last_name>
    <phone>312-926-1094</phone>
    <email>maciej.lesniak@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Amidei, RN</last_name>
    <phone>312-926-1094</phone>
    <email>christina.amidei@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Amidei, RN, PhD</last_name>
      <email>christina.amidei@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maciej Lesniak, MD</last_name>
      <phone>3129261094</phone>
      <phone_ext>Lesniak</phone_ext>
      <email>maciej.lesniak@northwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tobias AL, Thaci B, Auffinger B, Rincón E, Balyasnikova IV, Kim CK, Han Y, Zhang L, Aboody KS, Ahmed AU, Lesniak MS. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med. 2013 Sep;2(9):655-66. doi: 10.5966/sctm.2013-0039. Epub 2013 Aug 7.</citation>
    <PMID>23926209</PMID>
  </reference>
  <reference>
    <citation>Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, Kim CK, Yunis C, Han Y, Alexiades NG, Fan X, Aboody KS, Lesniak MS. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013 Jul 3;105(13):968-77. doi: 10.1093/jnci/djt141.</citation>
    <PMID>23821758</PMID>
  </reference>
  <reference>
    <citation>Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.</citation>
    <PMID>21718006</PMID>
  </reference>
  <reference>
    <citation>Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS, Lesniak MS. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 2011 Sep;19(9):1714-26. doi: 10.1038/mt.2011.100. Epub 2011 May 31.</citation>
    <PMID>21629227</PMID>
  </reference>
  <reference>
    <citation>Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 2009 Apr 7;100(7):1154-64. doi: 10.1038/sj.bjc.6604969. Epub 2009 Mar 10.</citation>
    <PMID>19277041</PMID>
  </reference>
  <reference>
    <citation>Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB, Lesniak MS. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 2008 Jul 15;68(14):5778-84. doi: 10.1158/0008-5472.CAN-07-6441.</citation>
    <PMID>18632631</PMID>
  </reference>
  <reference>
    <citation>Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007 Jul;18(7):589-602.</citation>
    <PMID>17630837</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>New Diagnosed Glioma</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Radiation</keyword>
  <keyword>Neural Stem Cells</keyword>
  <keyword>Virotherapy</keyword>
  <keyword>Adenovirus</keyword>
  <keyword>Oncolytic virotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

